PAVmed (PAVM) Net Equity Issued and Repurchased (2019 - 2025)

PAVmed's Net Equity Issued and Repurchased history runs 7 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 229.89% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $2.5 million, a 112.11% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased advanced to $1.6 million in Q4 2025 per PAVM's latest filing, from $841000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $54.9 million in Q4 2021 and bottomed at -$1.3 million in Q4 2024.
• The 5-year median for Net Equity Issued and Repurchased is $304000.0 (2021), against an average of $7.6 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 4956.67% in 2023 and tumbled 187.03% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $54.9 million in 2021, then tumbled by 100.05% to -$30000.0 in 2022, then jumped by 4956.67% to $1.5 million in 2023, then tumbled by 187.03% to -$1.3 million in 2024, then surged by 229.89% to $1.6 million in 2025.
• Per Business Quant, the three latest PAVM Net Equity Issued and Repurchased figures stand at $1.6 million (Q4 2025), $841000.0 (Q1 2025), and -$1.3 million (Q4 2024).